Cingulate Inc, commonly abbreviated as CING, is a pioneering biopharmaceutical company primarily focused on the development and commercialization of innovative medicines designed to service patients who suffer from CNS disorders (Central Nervous System disorders). Founded by a group of experienced professionals with long-standing track records in the pharmaceutical industry. The team is composed of accomplished executives and scientific advisors who have success in developing, registering, and launching several widely-used CNS pharmaceutical products.
Combining their expertise with strategic partnerships, CING is at the forefront of transforming the approach towards addressing CNS disorders. The company is deeply committed to providing solutions that offer improved patient experiences, better therapeutic outcomes, and a higher quality of life for patients suffering from debilitating neurological and psychiatric conditions.
In terms of research and development, the team at Cingulate is specifically developing products using the company’s proprietary "accudel" drug delivery technology. This unique approach to drug delivery is designed to offer significant advantages over currently available treatments, such as greater accuracy, targeted delivery, extended relief, and improved patient compliance.
The company's most advanced product candidate is CING-001, a novel, rapid-acting, small molecule investigational drug for the acute treatment of treatment-resistant depression (TRD) and suicidality in major depressive disorder (MDD). It is being developed with the aim to meet the significant unmet patient needs in these indications, given the limitations of current antidepressant medications.
Cingulate’s strategy includes covering the entire life-cycle of their product—from the early discovery to the commercial launch—while seeking strategic collaborations, partnerships, and out-licensing deals to maximize the value and impact of their drug portfolio.
Cingulate Inc. operates at the intersection of innovation, technology, and healthcare, with the unified mission to enhance patient quality of life and provide more hopeful and effective treatment pathways for people living with CNS disorders. As a patient-centric company, the goal is not only to address unmet medical needs but also to do so with the highest level of care, understanding, and commitment to patient well-being.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cingulate Inc.'s Chairman and CEO, Shane J. Schaffer, and Chief Commercial Officer, Bryan Downey, will present at the Indegene Digital Summit. They will discuss Cingulate's "SMART Launch" approach, focusing on how emerging pharmaceutical companies can commercialize products effectively and efficiently without extensive internal infrastructure. The discussion will include strategies for launching CTx-1301, Cingulate's lead asset for ADHD treatment, and address the economics of pharmaceutical launches, partner ecosystems, and risk reduction.
Ascendiant Capital Markets has reduced its target price for CINGULATE INC (CING.O) to $44 from $52. This update reflects a change in the analyst's outlook for the company. The article, sourced from Reuters, was published on August 20, 2026.
Ascendiant Capital Markets has reduced its price target for Cingulate (NASDAQ:CING) from $52.00 to $44.00, while maintaining a "buy" rating. Despite the lowered target, the consensus among four analysts remains a "Moderate Buy" with an average price target of $24.67. Cingulate recently reported a narrower-than-expected quarterly loss of $0.45 per share, and institutional investors currently hold approximately 41.31% of the company's stock.
Dr. Shane J. Schaffer, CEO of Cingulate Inc. (NASDAQ: CING), explains how a child's ADHD diagnosis frequently leads to parents recognizing similar symptoms in themselves, highlighting ADHD's strong heritability. He discusses how cultural shifts, improved public understanding, and reduced stigma are contributing to increased awareness and self-reflection among adults. Schaffer also notes that advancements in treatment, like Cingulate's potential once-daily medication, aim to provide more consistent symptom control and improve outcomes for entire families across generations.
Cingulate Inc. reported a net loss of $5.9 million for the second quarter of 2026, with cash and cash equivalents totaling $28.4 million. The company is preparing for a resubmission of its CTx-1301 ADHD treatment NDA following an FDA Complete Response Letter. Cingulate anticipates its current cash balance will fund operations into mid-2027 and has partnered with Prasco, LLC for commercial distribution of CTx-1301.